FDA clears Lutronic's Spectra VRM III for dermatological, aesthetic treatments
June 2, 2008 -- Lutronic, a developer and manufacturer of medical laser systems, says it has received FDA clearance to market its Spectra VRM III. This dual pulse Q-Switched Nd:Yag laser is the feature-rich successor to the Spectra VRM II. The laser produces 4 wavelengths (1064 nm, 532 nm, 585 nm, 650 nm) in Q-switched nanosecond pulse. It is specifically designed to treat a wide array of dermatological and aesthetic conditions, including dermal and epidermal pigmented lesions, multicolor tattoos, melasma, and active acne. It further enables laser toning, and non-ablative photo-acoustic skin rejuvenation techniques.
The laser incorporates a dual pulse mode, which enables it to produce very short and quasi-long microsecond pulses. There are numerous advantages which result from the unique pulse characteristics not found in other lasers including extreme high peak power and a flat-top beam profile. "The VRM III is extremely effective for the treatment of melasma. I have been achieving near 100% clearance on melasma treatment therapy. This is very impressive because melasma is traditionally thought to be treatment resistant. Further, the VRM has also been highly effective for the treatment of Post-Inflammatory Hyperpigmentation that may result as adverse side affects from other lasers or IPL treatments," explains Dr. Sooil Chun, the clinical professor of Yonsei University. The company states that further scientific works are being conducted for this treatment in an effort to collect additional empirical data for peer reviewed studies.
As tattoo removal is becoming one of the fastest-growing treatment groups, the 4 wavelength option offered by the VRM III laser enables treatment of a wide range of colors. The laser's flat-top beam profile provides increased patient comfort and reduced pinpoint bleeding, resulting in fewer side effects and significantly faster healing. The fine control of the 532 nm wavelength feature assures that epidermal lesions are treated with measurably less potential for PIH.
Lutronic's VRM series has an installed base of more than 2000 units globally.